ABOUT RYBODYN

WHO WE ARE

RyboDyn is a pioneering immunotherapy developer on a mission to transform the way we approach human health. By unlocking the secrets of the dark proteome, we’re redefining patient care with breakthrough therapies that target previously hidden markers of disease. Our innovative approach—powered by our proprietary RyboCypher™ technology—sets us apart as leaders in the field of next-generation immunotherapies.

OUR MISSION

To transform hidden biology into actionable insights and deliver first-in-class immunotherapies that revolutionize patient care.

OUR STORY

At RyboDyn, our journey began with a simple yet powerful question: What if the mysteries hidden within our genetic code could be the key to life-saving treatments? We set out to explore the uncharted territories of the dark genome and dark proteome—vast realms that conventional methods overlook. Through relentless research and innovation, we discovered unique Dark Targets™ that form the foundation of our breakthrough immunotherapies.

RYBODYN TEAM

  • Imad Ajjawi

    IMAD AJJAWI, PHD, MBA

    Co-Founder & Chief Executive Officer

  • Corey Dambacher

    COREY DAMBACHER, PHD

    Founder, President, & Chief Technology Officer

  • Kerry Wilson

    KERRY WILSON, PHD

    Co-Founder & VP, Platform Development

  • Ashley Woodfin

    ASHLEY WOODFIN, MSC

    Co-Founder & Bioinformatics Lead - Target Discovery

  • Andy Bass

    ANDY BASS

    VP, Marketing & Communications

  • MARCO BLANCHETTE

    MARCO BLANCHETTE, PHD

    VP, Target Discovery

  • JOEL CHICK

    JOEL CHICK, PHD

    VP, Proteomics Discovery

  • Leo Garnar-Wortzel

    LEO GARNAR-WORTZEL, PHD

    Scientist

  • Ariel Schwartz

    ARIEL SCHWARTZ, PHD

    VP, AI

  • Jessica Weir

    JESSICA WEIR

    Senior Associate Scientist

ADVISORY TEAM

  • Gordon B. Mills

    GORDON B. MILLS, MD, PHD

    Clinical & Scientific Advisor

  • Neeha Zaidi

    NEEHA ZAIDI, MD

    Clinical & Scientific Advisor

  • Todd Peterson

    TODD PETERSON, PHD

    Life Science Business Advisor

  • Richard Kurtz

    RICHARD KURTZ, PHD

    Life Science Business Advisor

  • Alex Jarger

    ALEX JAEGER, PHD

    Academic Co-Founder, Scientific Advisor

  • Jose´Morachis

    JOSÉ MORACHIS, PHD

    Investor, Scientific Advisor

  • Will Alaynick

    WILL ALAYNICK, PHD

    Investor, Scientific Advisor

OUR INVESTORS *

OUR PARTNERS *

OUR INVESTORS * OUR PARTNERS *